PHASE I TRIAL INITIATION REQUIREMENTS ARE BEING DISCUSSED BY FDA
Executive Summary
PHASE I TRIAL INITIATION REQUIREMENTS ARE BEING DISCUSSED BY FDA and industry groups in a series of meetings concerning the differences between FDA's paperwork requirements and those outside the U.S. for beginning human clinical studies. The agency expects to finish dialogues with outside groups this summer and come up with recommendations on how FDA's procedures for allowing the start of Phase I studies might be streamlined to be more on par with procedures in Europe.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth